Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003937 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 253
- Enrollment target
NCT00003937 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 253 participants.
The verdict
NCT00003937, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 253 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase III trial to study the effectiveness of three combination chemotherapy regimens plus dexrazoxane in treating patients who have newly diagnosed nonmetastatic osteosarcoma.
Interventions
- DRUG cisplatin
- DRUG etoposide
- DRUG ifosfamide
- DRUG dexrazoxane hydrochloride
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 1999-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003937
The ClinicalTrials.gov registry entry for NCT00003937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003937 about?
NCT00003937 is a clinical study titled "Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II...
What is the current status of trial NCT00003937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 253 participants. The study started on 1999-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00003937?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), ifosfamide (DRUG), dexrazoxane hydrochloride (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003937?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.